A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the efficacy and safety of Camrelizumab in
combination with nb-Paclitaxel in treating patients with recurrent/metastatic non-small-cell
lung cancer.